Summary of Orthofix Medical Q3 2025 Conference Call Company Overview - **Company**: Orthofix Medical (NasdaqGS: OFIX) - **Date**: November 12, 2025 - **Key Focus**: Discussion of Q3 2025 financial performance and future outlook Key Highlights Financial Performance - **Q3 Revenue**: Beat consensus by approximately $3 million, achieving a revenue growth of 6% [3][5] - **EBITDA Margin**: Experienced a 230 basis points expansion, marking the seventh consecutive quarter of EBITDA margin growth [3] - **Free Cash Flow**: Positive free cash flow of $2.5 million in Q3 [3] Market Dynamics - **U.S. Spine Growth**: Strong procedure growth at 10%, with expectations to continue growing above market rates [9][10] - **International Orders**: Q3 revenue beat primarily driven by earlier-than-expected international stocking orders [6][7] Product and Strategy Insights - **Distributor Transition**: Ongoing consolidation of a fragmented distributor network is expected to drive incremental growth [14][16] - **7D Placement Demand**: Positive trends noted in capital equipment demand, with a focus on earn-out agreements to reduce upfront costs for hospitals [18][21] - **Verada Launch**: The new product is designed to enhance user experience in the operating room, with a full launch expected in 2026 [25][30] Future Outlook - **2026 Expectations**: Anticipated positive growth driven by the Verada launch, full-year impact from distributor transitions, and new product introductions [34] - **BGT Revenue Impact**: CMS pilot program expected to have an immaterial annual impact on BGT revenue, with no change in physician prescribing behavior anticipated [38][39] Margin and Profitability Goals - **Gross Margin Expansion**: Targeting 300 basis points of gross margin expansion by 2027, driven by supplier consolidation and insourcing strategies [40][42] - **EBITDA Margin Goals**: Aiming for mid-teens EBITDA margins by 2027, with a focus on leveraging operational efficiencies [47][56] Orthopedics Business Outlook - **Growth Potential**: Positive outlook for the Orthopedics segment, particularly in trauma and diabetic foot treatment markets, with significant product differentiation [58][59] Underappreciated Aspects - **Company Transformation**: Notable improvements in free cash flow and consistent EBITDA performance are seen as underappreciated by the market [61][62] Additional Insights - **Pricing Strategy**: Long-term guidance assumes 1% to 2% price erosion, but current pricing has remained relatively flat [12] - **Market Positioning**: Orthofix aims to leverage its innovative product lines and strong distributor relationships to capture market share [10][16] This summary encapsulates the key points discussed during the conference call, highlighting the company's financial performance, market dynamics, product strategies, and future outlook.

Core Insights - OrthoPediatrics Corp. reported a 12% year-over-year increase in total revenue for Q3 2025, reaching $61.2 million, and a 56% increase in adjusted EBITDA to $6.2 million [4][15][17] Financial Performance - Total revenue for Q3 2025 was $61.2 million, up from $54.6 million in Q3 2024, with U.S. revenue increasing by 14% to $48.7 million, representing 80% of total revenue [4][6] - International revenue grew by 6% to $12.5 million, accounting for 20% of total revenue, driven by strong performance in Trauma and Deformity, Scoliosis, and OP Specialty Bracing [4][6] - Trauma and Deformity revenue increased by 17% to $44.1 million, while Scoliosis revenue rose by 4% to $16.3 million [5][31] - Gross profit for Q3 2025 was $45.3 million, a 13% increase from $40.1 million in Q3 2024, with a gross profit margin of 74% [6][7] - Operating expenses increased by 20% to $54.7 million, primarily due to restructuring charges and increased non-cash stock compensation [8][10] Strategic Initiatives - The company aims to achieve free cash flow break-even by 2026 through strategic initiatives such as scaling OPSB and introducing innovative products [3] - OrthoPediatrics completed its first procedures with the VerteGlide™ Spinal Growth Guidance System and received FDA approval for the 3P™ Pediatric Plating Platform™ Small-Mini System [6][17] Guidance and Outlook - Full year 2025 revenue guidance is set between $233.5 million and $234.5 million, reflecting a growth of 14% to 15% compared to the previous year [17] - The company reiterated its annual set deployment target of $15.0 million and adjusted EBITDA guidance of $15.0 million to $17.0 million for the full year [17]